総資産利益率 (ROA)
2012年から
難易度が低い
計算
AbbVie Inc., ROA, 長期的な傾向、計算
| ROA | = | 100 | × | 純利益1 | ÷ | 総資産1 | |
|---|---|---|---|---|---|---|---|
| 2019/12/31 | 8.84% | = | 100 | × | 7,882 | ÷ | 89,115 |
| 2018/12/31 | 9.58% | = | 100 | × | 5,687 | ÷ | 59,352 |
| 2017/12/31 | 7.50% | = | 100 | × | 5,309 | ÷ | 70,786 |
| 2016/12/31 | 9.01% | = | 100 | × | 5,953 | ÷ | 66,099 |
| 2015/12/31 | 9.70% | = | 100 | × | 5,144 | ÷ | 53,050 |
| 2014/12/31 | 6.44% | = | 100 | × | 1,774 | ÷ | 27,547 |
| 2013/12/31 | 14.14% | = | 100 | × | 4,128 | ÷ | 29,198 |
| 2012/12/31 | 19.53% | = | 100 | × | 5,275 | ÷ | 27,008 |
ソース： AbbVie Inc. (NYSE:ABBV) | Return on Assets since 2012 (www.stock-analysis-on.net)
1 百万ドル
競合他社との比較
AbbVie Inc., ROA, 長期的な傾向、競合他社との比較
| AbbVie Inc. | Abbott Laboratories | Amgen Inc. | Bristol-Myers Squibb Co. | Eli Lilly & Co. | Gilead Sciences Inc. | Illumina Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Vertex Pharmaceuticals Inc. | Zoetis Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2019/12/31 | 8.84% | 5.43% | 13.13% | 2.65% | 21.17% | 8.74% | 13.70% | 9.59% | 11.66% | 9.72% | 14.29% | 14.15% | 12.99% |
| 2018/12/31 | 9.58% | 3.53% | 12.64% | 14.06% | 7.36% | 8.57% | 11.87% | 10.00% | 7.53% | 7.00% | 20.83% | 33.57% | 13.25% |
| 2017/12/31 | 7.50% | 0.63% | 2.48% | 3.00% | -0.45% | 6.58% | 13.81% | 0.83% | 2.72% | 12.40% | 13.67% | 7.43% | 10.06% |
| 2016/12/31 | 9.01% | 2.66% | 9.95% | 13.22% | 7.05% | 23.70% | 10.81% | 11.71% | 4.11% | 4.20% | 12.84% | -3.87% | 10.73% |
| 2015/12/31 | 9.70% | 10.72% | 9.69% | 4.93% | 6.77% | 34.93% | 12.52% | 11.55% | 4.36% | 4.16% | 11.34% | -22.26% | 4.28% |
| 2014/12/31 | 6.44% | 5.53% | 7.47% | 5.94% | 6.43% | 34.91% | 10.58% | 12.45% | 12.12% | 5.40% | 8.99% | -31.63% | 8.82% |
| 2013/12/31 | 14.14% | 6.00% | 7.68% | 6.64% | 13.29% | 13.67% | 4.15% | 10.42% | 4.17% | 12.78% | 14.38% | -19.19% | 7.69% |
| 2012/12/31 | 19.53% | 8.87% | 8.00% | 5.46% | 11.89% | 12.20% | 5.89% | 8.94% | 5.81% | 7.84% | 36.06% | -3.88% | 6.96% |
ソース： AbbVie Inc. (NYSE:ABBV) | Return on Assets since 2012 (www.stock-analysis-on.net)
産業部門との比較： 医薬品とバイオテクノロジー
AbbVie Inc., ROA, 長期的な傾向、産業部門との比較： 医薬品とバイオテクノロジー
| AbbVie Inc. | 医薬品とバイオテクノロジー | |
|---|---|---|
| 2019/12/31 | 8.84% | 9.30% |
| 2018/12/31 | 9.58% | 9.07% |
| 2017/12/31 | 7.50% | 5.04% |
| 2016/12/31 | 9.01% | 8.67% |
| 2015/12/31 | 9.70% | 9.37% |
| 2014/12/31 | 6.44% | 9.67% |
| 2013/12/31 | 14.14% | 9.54% |
| 2012/12/31 | 19.53% | 8.55% |
ソース： AbbVie Inc. (NYSE:ABBV) | Return on Assets since 2012 (www.stock-analysis-on.net)
業界との比較： 健康管理
AbbVie Inc., ROA, 長期的な傾向、業界との比較： 健康管理
| AbbVie Inc. | 健康管理 | |
|---|---|---|
| 2019/12/31 | 8.84% | 8.44% |
| 2018/12/31 | 9.58% | 7.94% |
| 2017/12/31 | 7.50% | 5.12% |
| 2016/12/31 | 9.01% | 7.42% |
| 2015/12/31 | 9.70% | 7.66% |
| 2014/12/31 | 6.44% | 8.68% |
| 2013/12/31 | 14.14% | 8.86% |
| 2012/12/31 | 19.53% | 7.77% |
ソース： AbbVie Inc. (NYSE:ABBV) | Return on Assets since 2012 (www.stock-analysis-on.net)